Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals Inc (MDGL) - Total Assets
Latest total assets as of September 2025: $1.36 Billion USD
Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) holds total assets worth $1.36 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Madrigal Pharmaceuticals Inc - Total Assets Trend (2001–2024)
This chart illustrates how Madrigal Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Madrigal Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Madrigal Pharmaceuticals Inc's total assets of $1.36 Billion consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.6% |
| Accounts Receivable | $53.82 Million | 5.2% |
| Inventory | $34.07 Million | 3.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.73 Million | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Madrigal Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Madrigal Pharmaceuticals Inc's current assets represent 99.1% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2024, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 5.2% of total assets.
Madrigal Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Madrigal Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Madrigal Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Madrigal Pharmaceuticals Inc generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Madrigal Pharmaceuticals Inc is currently not profitable relative to its asset base.
Madrigal Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.44 | 5.98 | 6.13 |
| Quick Ratio | 3.26 | 5.93 | 6.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $955.27 Million | $ 885.82 Million | $ 238.61 Million |
Madrigal Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Madrigal Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.87 |
| Latest Market Cap to Assets Ratio | 5.11 |
| Asset Growth Rate (YoY) | 62.7% |
| Total Assets | $1.04 Billion |
| Market Capitalization | $5.33 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Madrigal Pharmaceuticals Inc's assets at a significant premium ( 5.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Madrigal Pharmaceuticals Inc's assets grew by 62.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Madrigal Pharmaceuticals Inc (2001–2024)
The table below shows the annual total assets of Madrigal Pharmaceuticals Inc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.04 Billion | +62.71% |
| 2023-12-31 | $640.55 Million | +76.67% |
| 2022-12-31 | $362.57 Million | +32.65% |
| 2021-12-31 | $273.33 Million | -4.76% |
| 2020-12-31 | $287.00 Million | -35.08% |
| 2019-12-31 | $442.06 Million | -8.93% |
| 2018-12-31 | $485.43 Million | +152.42% |
| 2017-12-31 | $192.31 Million | +366.67% |
| 2016-12-31 | $41.21 Million | -39.57% |
| 2015-12-31 | $68.19 Million | -32.26% |
| 2014-12-31 | $100.67 Million | +5.75% |
| 2013-12-31 | $95.20 Million | -7.59% |
| 2012-12-31 | $103.02 Million | +143.40% |
| 2011-12-31 | $42.32 Million | -21.72% |
| 2010-12-31 | $54.07 Million | +10.54% |
| 2009-12-31 | $48.91 Million | -49.71% |
| 2008-12-31 | $97.25 Million | -20.71% |
| 2007-12-31 | $122.65 Million | +123.86% |
| 2006-12-31 | $54.79 Million | -23.06% |
| 2005-12-31 | $71.21 Million | -46.06% |
| 2004-12-31 | $132.02 Million | +64.23% |
| 2003-12-31 | $80.39 Million | +2798.92% |
| 2001-12-31 | $2.77 Million | -- |